Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...

Do those on Zepbound have to switch to Wegovy after Caremark drops Zepbound from preferred coverage? What options are there?

Both semaglutide and tirzepatide for type 2 diabetes and weight loss are GLP-1 agonists, meaning they mimic the hormone.

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

CVS Caremark has removed coverage of Zepbound, a GLP-1 weight-loss drug, citing pricing concerns and shifting payer dynamics ...

GOP leaders are racing to try to get the bill to the White House by July 4. The multi-trillion-dollar bill would unlock tax ...

The drug is now available for prescription in New Zealand but there are clouds to go along with the silver linings - such as ...

The first study to put two GLP-1 weight loss drugs head-to-head found Zepbound helped people lose more weight than Wegovy.

Danish drugmaker Novo Nordisk is working to bring its blockbuster drug Ozempic to India “as soon as possible", Dr Yan Cai, ...

Insurers are cutting coverage, citing costs. But there’s seldom any discussion of the return on investment from these drugs ...

Earlier this week, semaglutide drugs Ozempic and Wegovy were made available for prescription in New Zealand. Semaglutide ...